RGLS

Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RGLS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/18	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/18	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/16	21 : 00	PR Newswire (US)	Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05 : 54	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05 : 27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/10	05 : 05	PR Newswire (US)	Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/05/06	21 : 00	PR Newswire (US)	Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/04/30	21 : 00	PR Newswire (US)	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/03/22	05 : 05	PR Newswire (US)	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/03/12	19 : 32	PR Newswire (US)	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/03/12	19 : 30	PR Newswire (US)	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/19	10 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/19	10 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/18	07 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/18	07 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/13	06 : 11	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/10	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:RGLS	Regulus Therapeutics Inc
2024/01/03	06 : 05	PR Newswire (US)	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/12/28	06 : 16	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/22	22 : 00	PR Newswire (US)	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/10	06 : 39	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/10	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/10	06 : 05	PR Newswire (US)	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/11/02	21 : 00	PR Newswire (US)	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/10/19	21 : 00	PR Newswire (US)	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc
2023/09/20	20 : 00	PR Newswire (US)	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	NASDAQ:RGLS	Regulus Therapeutics Inc